FDA clears Opus Genetics' IND for RDH12-LCA gene therapy

Opus Genetics has received FDA clearance for its IND application of OPGx-RDH12, a gene therapy targeting RDH12-associated Leber congenital amaurosis, an inherited retinal disease causing early childhood blindness. This investigational AAV-based therapy aims to deliver a functional RDH12 gene to retinal photoreceptors, backed by supportive preclinical safety and efficacy data.

This Wire brief sits within Fusion42's coverage of Biotech.